Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older

INTRODUCTION: In phase III trials in adolescents and children with atopic dermatitis (AD), dupilumab significantly decreased global disease severity. However, the effects of dupilumab on the extent and signs of AD across different anatomical regions were not reported. Here we characterize the effica...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Thaçi, Diamant, Wollenberg, Andreas, Cork, Michael J., Marcoux, Danielle, Huang, Rui, Chen, Zhen, Rossi, Ana B., Shumel, Brad, Sierka, Debra, Bansal, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484382/
https://www.ncbi.nlm.nih.gov/pubmed/34427891
http://dx.doi.org/10.1007/s13555-021-00568-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8484382/
https://www.ncbi.nlm.nih.gov/pubmed/34427891
http://dx.doi.org/10.1007/s13555-021-00568-y

Ejemplares similares